Insys Therapeutics Inc (INSY) 62.10 $INSY
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part V
Anthony Cataldo - at Seeking Alpha - Sat Apr 18, 6:09AM CDT
INSY: 62.10 (+0.76)
NTRR Reviews Latest Cannabis Innovations at Denver's Big Industry Show
Business Wire - Thu Apr 16, 4:00AM CDT
Neutra Corp. (OTCBB: NTRR) CEO Chris Brown traveled to Colorado this week to meet with retailers and review the latest products and innovations in the cannabis industry at the annual Big Industry Show in Denver.
INSY: 62.10 (+0.76)
5 Biotechnology Bargains Revisited
Joseph P. Porter - at Seeking Alpha - Wed Apr 15, 8:22AM CDT
INSY: 62.10 (+0.76), BSTC: 37.64 (-0.29), NLNK: 53.12 (-0.07), ENTA: 36.99 (+0.01), ANIK: 38.68 (+0.05)
Short Interest In Insys Therapeutics Expands By 10.7%
MarketNewsVideo.com - Tue Apr 14, 3:28PM CDT
The most recent short interest data has been released by the NASDAQ for the 03/31/2015 settlement date, which shows a 610,489 share increase in total short interest for Insys Therapeutics Inc , to 6,331,104, an increase of 10.67% since 03/13/2015. ...
INSY: 62.10 (+0.76)
NTRR: Preliminary Results of Horticultural Product Testing Exceed Expectations
Business Wire - Tue Apr 14, 8:42AM CDT
The preliminary results of lab testing on the suite of horticultural products being marketed by Neutra Corp. (OTCBB: NTRR) and its joint venture partner, Surface to Air Solutions, Inc. (S2O2), have so far exceeded all expectations, the company announced today.
INSY: 62.10 (+0.76)
GTSO Plans Edibles Tour of California and Colorado to Refine Market Strategy
Business Wire - Tue Apr 14, 8:39AM CDT
As Green Technology Solutions, Inc. (OTCBB: GTSO) works to develop new products for the booming U.S. cannabis edibles market, representatives of the company will travel to California and Colorado--two the of the country's biggest marketplaces for edibles--to meet with retailers and refine its strategy to better serve the demands of dispensaries nationwide.
INSY: 62.10 (+0.76)
NTRR and S2O2 Deliver New Weapons Against Mold in Colorado's Billion-Dollar Cannabis Industry
Business Wire - Thu Apr 09, 4:00AM CDT
As the state government agencies work to eliminate the threat of mold contamination in Colorado's booming cannabis industry, Neutra Corp. (OTCBB:NTRR) and its joint venture partner, Surface to Air Solutions, Inc. (S2O2), stand ready with a possible solution to the problem.
INSY: 62.10 (+0.76)
NTRR Joint Venture Offers New Antimicrobial Solutions to Embattled Colorado Cannabis Growers
Business Wire - Tue Apr 07, 6:21AM CDT
As testing continues in Colorado on horticultural products marketed by Neutra Corp. (OTCBB:NTRR) and its joint venture partner, Surface to Air Solutions (S2O2), the companies are already receiving a great deal of interest from cannabis growers in the state. In response, each Friday in April, S2O2 will conduct educational information sessions on its suite of antimicrobial alternatives to pesticides, hosted by respected cultivation organization Denver Consulting Group.
INSY: 62.10 (+0.76)
Shortage of Qualified Cannabis Testing Labs Spells Opportunity for GTSO
Business Wire - Tue Apr 07, 6:05AM CDT
A distinct shortage of Colorado labs equipped to test adult-use cannabis for contaminants such as bacteria and mold could produce major opportunities for Green Technology Solutions, Inc. (OTCBB:GTSO).
INSY: 62.10 (+0.76)
The Best Stocks to Invest in Marijuana
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 04, 1:08PM CDT
The 2014 elections created a lot of excitement among marijuana supporters, as voters in Oregon, Alaska, and the District of Columbia expanded the number of jurisdictions allowing recreational marijuana use. This has policy makers thinking 2016...
INSY: 62.10 (+0.76), GWPH: 113.04 (-0.05)
Don't Play With Propane - Cramer's Lightning Round (4/1/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Apr 02, 6:02AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, April 1. Bullish Calls: Insys Therapeutics (NASDAQ: INSY ): "Good company. Makes money, but be careful because Johnson & Johnson (NYSE: JNJ )...
MNK: 122.95 (-2.22), KMI: 44.07 (+0.46), KSS: 75.91 (+0.96), MCK: 231.27 (-0.02), UNH: 117.81 (-1.47), ALK: 64.31 (-0.62), AGEN: 6.08 (+0.21), URBN: 42.17 (+0.03), DDS: 136.44 (-0.34), SBUX: 48.33 (-0.04), JNJ: 100.43 (+0.13), HCA: 77.53 (-0.15), INSY: 62.10 (+0.76), DNKN: 47.72 (+0.21), AMAT: 22.31 (+0.02), FGP: 23.82 (+0.22), BIG: 47.15 (+0.11), KPTI: 32.24 (-0.60)
'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners
at The Street - Thu Apr 02, 5:00AM CDT
Cramer says to be careful on Insys Therapeutics, prefers Starbucks over Dunkin Brands and would buy Alaska Air.
KMI: 44.07 (+0.46), KSS: 75.91 (+0.96), MCK: 231.27 (-0.02), UNH: 117.81 (-1.47), ALK: 64.31 (-0.62), URBN: 42.17 (+0.03), SBUX: 48.33 (-0.04), AGEN: 6.08 (+0.21), DDS: 136.44 (-0.34), HCA: 77.53 (-0.15), DNKN: 47.72 (+0.21), INSY: 62.10 (+0.76), AMAT: 22.31 (+0.02), FGP: 23.82 (+0.22), BIG: 47.15 (+0.11), KPTI: 32.24 (-0.60)
NTRR Scouts Opportunities in New Cannabis States to Offer Cleaner Growing Solutions
Business Wire - Thu Apr 02, 4:00AM CDT
As cannabis reform continues to sweep across North America from coast to coast, Neutra Corp. (OTCBB: NTRR) will pursue new opportunities to improve cultivation methods in territories where the plant is legal and regulated with a ground-breaking suite of horticultural products.
INSY: 62.10 (+0.76)
GTSO Engineers New Solutions to Colorado Cannabis Industry's Pesticides Problem
Business Wire - Thu Apr 02, 4:00AM CDT
As Green Technology Solutions, Inc. (OTCBB:GTSO) works to establish its new cannabis testing laboratory, state regulators in Colorado are stepping in to ensure that all cannabis products under their jurisdiction are free from potentially harmful pesticides and other contaminants.
INSY: 62.10 (+0.76)
Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride
at The Street - Wed Apr 01, 7:22PM CDT
Supply is the true enemy of the bull and there's a lot of new supply hitting the markets, Cramer says.
CXO: 123.60 (+0.33), KMI: 44.07 (+0.46), TSLA: 219.44 (+10.03), KSS: 75.91 (+0.96), GE: 26.91 (+0.29), EMES: 51.50 (+0.20), FRPT: 22.79 (-0.60), UTX: 116.96 (+0.01), UNH: 117.81 (-1.47), FCX: 20.57 (+0.34), BPT: 67.68 (+1.51), SDRL: 11.33 (+0.28), SLB: 92.16 (+0.87), SBUX: 48.33 (-0.04), DNKN: 47.72 (+0.21), INSY: 62.10 (+0.76), LNCO: 12.34 (+0.46), AMAT: 22.31 (+0.02), CRZO: 52.72 (+0.32), FGP: 23.82 (+0.22), AAPL: 128.62 (+1.71), SIRI: 3.94 (unch), ABT: 48.35 (+1.23), MCK: 231.27 (-0.02), BMY: 66.60 (-0.21), ALK: 64.31 (-0.62), ARP: 9.04 (-0.02), URBN: 42.17 (+0.03), DDS: 136.44 (-0.34), AGEN: 6.08 (+0.21), PM: 83.69 (-0.36), HCA: 77.53 (-0.15), RDS.A: 62.36 (-0.06), TXMD: 7.17 (+0.01), BIG: 47.15 (+0.11), GDDY: 24.77 (-0.01), KPTI: 32.24 (-0.60)
Insys Therapeutics Inc. Poised For Strong Growth In Earnings Ahead
Christopher Stoehr - at Seeking Alpha - Wed Apr 01, 7:43AM CDT
INSY: 62.10 (+0.76), GWPH: 113.04 (-0.05), PFNX: 15.12 (+0.42)
Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phwnn8/lennoxgastaut) has announced the addition of the "Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Lennox-Gastaut Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lennox-Gastaut Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lennox-Gastaut Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Lennox-Gastaut Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - H. Lundbeck A/S - GW Pharmaceuticals plc - INSYS Therapeutics, Inc. - SymPhar Sp. z.o.o. - ProductLife Group SA - Mylan Inc. - Johnson & Johnson - GlaxoSmithKline plc - Ajanta Pharma Limited For more information visit http://www.researchandmarkets.com/research/ph...noxgastaut
JNJ: 100.43 (+0.13), INSY: 62.10 (+0.76), GSK: 46.57 (-0.67)
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m8gr3t/recurrent) has announced the addition of the "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" report to their offering. Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Recurrent Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - INSYS Therapeutics, Inc. - Eli Lilly and Company - Eisai Co., Ltd. - TransMolecular, Inc. - Tactical Therapeutics, Inc - Shandong Lanjin Pharmaceuticals Co. Ltd - Oncolytics Biotech Inc. - Amgen Inc. - Alkermes Plc For more information visit http://www.researchandmarkets.com/research/m8gr3t/recurrent
INSY: 62.10 (+0.76), ONCY: 0.80 (unch), MRK: 57.69 (+0.03), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), ALKS: 62.60 (-0.24)
NTRR Partner S2O2 Signs LOI With Leading Cannabis Laboratory to Test Cutting-Edge Horticultural Products
Business Wire - Tue Mar 31, 4:00AM CDT
Just days after a letter of intent to test and demonstrate their cutting-edge horticultural products at indoor cannabis cultivation facilities in Colorado was made public, Neutra Corp. (OTCBB:NTRR) and its joint venture partner Surface to Air Solutions, Inc. (S2O2) announced today that the testing procedures will be undertaken by one of the country's top cannabis laboratories.
INSY: 62.10 (+0.76)
How The CARERS Act Could Impact Pot Stocks
Michael Weiss - at Seeking Alpha - Mon Mar 30, 4:07AM CDT
CARA: 12.98 (+0.15), INSY: 62.10 (+0.76), GWPH: 113.04 (-0.05)
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part V
Anthony Cataldo - at Seeking Alpha - Sat Apr 18, 6:09AM CDT
INSY: 62.10 (+0.76)
NTRR Reviews Latest Cannabis Innovations at Denver's Big Industry Show
Business Wire - Thu Apr 16, 4:00AM CDT
Neutra Corp. (OTCBB: NTRR) CEO Chris Brown traveled to Colorado this week to meet with retailers and review the latest products and innovations in the cannabis industry at the annual Big Industry Show in Denver.
INSY: 62.10 (+0.76)
5 Biotechnology Bargains Revisited
Joseph P. Porter - at Seeking Alpha - Wed Apr 15, 8:22AM CDT
INSY: 62.10 (+0.76), BSTC: 37.64 (-0.29), NLNK: 53.12 (-0.07), ENTA: 36.99 (+0.01), ANIK: 38.68 (+0.05)
Short Interest In Insys Therapeutics Expands By 10.7%
MarketNewsVideo.com - Tue Apr 14, 3:28PM CDT
The most recent short interest data has been released by the NASDAQ for the 03/31/2015 settlement date, which shows a 610,489 share increase in total short interest for Insys Therapeutics Inc , to 6,331,104, an increase of 10.67% since 03/13/2015. ...
INSY: 62.10 (+0.76)
NTRR: Preliminary Results of Horticultural Product Testing Exceed Expectations
Business Wire - Tue Apr 14, 8:42AM CDT
The preliminary results of lab testing on the suite of horticultural products being marketed by Neutra Corp. (OTCBB: NTRR) and its joint venture partner, Surface to Air Solutions, Inc. (S2O2), have so far exceeded all expectations, the company announced today.
INSY: 62.10 (+0.76)
GTSO Plans Edibles Tour of California and Colorado to Refine Market Strategy
Business Wire - Tue Apr 14, 8:39AM CDT
As Green Technology Solutions, Inc. (OTCBB: GTSO) works to develop new products for the booming U.S. cannabis edibles market, representatives of the company will travel to California and Colorado--two the of the country's biggest marketplaces for edibles--to meet with retailers and refine its strategy to better serve the demands of dispensaries nationwide.
INSY: 62.10 (+0.76)
NTRR and S2O2 Deliver New Weapons Against Mold in Colorado's Billion-Dollar Cannabis Industry
Business Wire - Thu Apr 09, 4:00AM CDT
As the state government agencies work to eliminate the threat of mold contamination in Colorado's booming cannabis industry, Neutra Corp. (OTCBB:NTRR) and its joint venture partner, Surface to Air Solutions, Inc. (S2O2), stand ready with a possible solution to the problem.
INSY: 62.10 (+0.76)
NTRR Joint Venture Offers New Antimicrobial Solutions to Embattled Colorado Cannabis Growers
Business Wire - Tue Apr 07, 6:21AM CDT
As testing continues in Colorado on horticultural products marketed by Neutra Corp. (OTCBB:NTRR) and its joint venture partner, Surface to Air Solutions (S2O2), the companies are already receiving a great deal of interest from cannabis growers in the state. In response, each Friday in April, S2O2 will conduct educational information sessions on its suite of antimicrobial alternatives to pesticides, hosted by respected cultivation organization Denver Consulting Group.
INSY: 62.10 (+0.76)
Shortage of Qualified Cannabis Testing Labs Spells Opportunity for GTSO
Business Wire - Tue Apr 07, 6:05AM CDT
A distinct shortage of Colorado labs equipped to test adult-use cannabis for contaminants such as bacteria and mold could produce major opportunities for Green Technology Solutions, Inc. (OTCBB:GTSO).
INSY: 62.10 (+0.76)
The Best Stocks to Invest in Marijuana
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 04, 1:08PM CDT
The 2014 elections created a lot of excitement among marijuana supporters, as voters in Oregon, Alaska, and the District of Columbia expanded the number of jurisdictions allowing recreational marijuana use. This has policy makers thinking 2016...
INSY: 62.10 (+0.76), GWPH: 113.04 (-0.05)
Don't Play With Propane - Cramer's Lightning Round (4/1/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Apr 02, 6:02AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, April 1. Bullish Calls: Insys Therapeutics (NASDAQ: INSY ): "Good company. Makes money, but be careful because Johnson & Johnson (NYSE: JNJ )...
MNK: 122.95 (-2.22), KMI: 44.07 (+0.46), KSS: 75.91 (+0.96), MCK: 231.27 (-0.02), UNH: 117.81 (-1.47), ALK: 64.31 (-0.62), AGEN: 6.08 (+0.21), URBN: 42.17 (+0.03), DDS: 136.44 (-0.34), SBUX: 48.33 (-0.04), JNJ: 100.43 (+0.13), HCA: 77.53 (-0.15), INSY: 62.10 (+0.76), DNKN: 47.72 (+0.21), AMAT: 22.31 (+0.02), FGP: 23.82 (+0.22), BIG: 47.15 (+0.11), KPTI: 32.24 (-0.60)
'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners
at The Street - Thu Apr 02, 5:00AM CDT
Cramer says to be careful on Insys Therapeutics, prefers Starbucks over Dunkin Brands and would buy Alaska Air.
KMI: 44.07 (+0.46), KSS: 75.91 (+0.96), MCK: 231.27 (-0.02), UNH: 117.81 (-1.47), ALK: 64.31 (-0.62), URBN: 42.17 (+0.03), SBUX: 48.33 (-0.04), AGEN: 6.08 (+0.21), DDS: 136.44 (-0.34), HCA: 77.53 (-0.15), DNKN: 47.72 (+0.21), INSY: 62.10 (+0.76), AMAT: 22.31 (+0.02), FGP: 23.82 (+0.22), BIG: 47.15 (+0.11), KPTI: 32.24 (-0.60)
NTRR Scouts Opportunities in New Cannabis States to Offer Cleaner Growing Solutions
Business Wire - Thu Apr 02, 4:00AM CDT
As cannabis reform continues to sweep across North America from coast to coast, Neutra Corp. (OTCBB: NTRR) will pursue new opportunities to improve cultivation methods in territories where the plant is legal and regulated with a ground-breaking suite of horticultural products.
INSY: 62.10 (+0.76)
GTSO Engineers New Solutions to Colorado Cannabis Industry's Pesticides Problem
Business Wire - Thu Apr 02, 4:00AM CDT
As Green Technology Solutions, Inc. (OTCBB:GTSO) works to establish its new cannabis testing laboratory, state regulators in Colorado are stepping in to ensure that all cannabis products under their jurisdiction are free from potentially harmful pesticides and other contaminants.
INSY: 62.10 (+0.76)
Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride
at The Street - Wed Apr 01, 7:22PM CDT
Supply is the true enemy of the bull and there's a lot of new supply hitting the markets, Cramer says.
CXO: 123.60 (+0.33), KMI: 44.07 (+0.46), TSLA: 219.44 (+10.03), KSS: 75.91 (+0.96), GE: 26.91 (+0.29), EMES: 51.50 (+0.20), FRPT: 22.79 (-0.60), UTX: 116.96 (+0.01), UNH: 117.81 (-1.47), FCX: 20.57 (+0.34), BPT: 67.68 (+1.51), SDRL: 11.33 (+0.28), SLB: 92.16 (+0.87), SBUX: 48.33 (-0.04), DNKN: 47.72 (+0.21), INSY: 62.10 (+0.76), LNCO: 12.34 (+0.46), AMAT: 22.31 (+0.02), CRZO: 52.72 (+0.32), FGP: 23.82 (+0.22), AAPL: 128.62 (+1.71), SIRI: 3.94 (unch), ABT: 48.35 (+1.23), MCK: 231.27 (-0.02), BMY: 66.60 (-0.21), ALK: 64.31 (-0.62), ARP: 9.04 (-0.02), URBN: 42.17 (+0.03), DDS: 136.44 (-0.34), AGEN: 6.08 (+0.21), PM: 83.69 (-0.36), HCA: 77.53 (-0.15), RDS.A: 62.36 (-0.06), TXMD: 7.17 (+0.01), BIG: 47.15 (+0.11), GDDY: 24.77 (-0.01), KPTI: 32.24 (-0.60)
Insys Therapeutics Inc. Poised For Strong Growth In Earnings Ahead
Christopher Stoehr - at Seeking Alpha - Wed Apr 01, 7:43AM CDT
INSY: 62.10 (+0.76), GWPH: 113.04 (-0.05), PFNX: 15.12 (+0.42)
Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phwnn8/lennoxgastaut) has announced the addition of the "Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Lennox-Gastaut Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lennox-Gastaut Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lennox-Gastaut Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Lennox-Gastaut Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - H. Lundbeck A/S - GW Pharmaceuticals plc - INSYS Therapeutics, Inc. - SymPhar Sp. z.o.o. - ProductLife Group SA - Mylan Inc. - Johnson & Johnson - GlaxoSmithKline plc - Ajanta Pharma Limited For more information visit http://www.researchandmarkets.com/research/ph...noxgastaut
JNJ: 100.43 (+0.13), INSY: 62.10 (+0.76), GSK: 46.57 (-0.67)
Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m8gr3t/recurrent) has announced the addition of the "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" report to their offering. Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Recurrent Malignant Glioma Therapeutics Clinical Trials - Merck & Co., Inc. - INSYS Therapeutics, Inc. - Eli Lilly and Company - Eisai Co., Ltd. - TransMolecular, Inc. - Tactical Therapeutics, Inc - Shandong Lanjin Pharmaceuticals Co. Ltd - Oncolytics Biotech Inc. - Amgen Inc. - Alkermes Plc For more information visit http://www.researchandmarkets.com/research/m8gr3t/recurrent
INSY: 62.10 (+0.76), ONCY: 0.80 (unch), MRK: 57.69 (+0.03), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), ALKS: 62.60 (-0.24)
NTRR Partner S2O2 Signs LOI With Leading Cannabis Laboratory to Test Cutting-Edge Horticultural Products
Business Wire - Tue Mar 31, 4:00AM CDT
Just days after a letter of intent to test and demonstrate their cutting-edge horticultural products at indoor cannabis cultivation facilities in Colorado was made public, Neutra Corp. (OTCBB:NTRR) and its joint venture partner Surface to Air Solutions, Inc. (S2O2) announced today that the testing procedures will be undertaken by one of the country's top cannabis laboratories.
INSY: 62.10 (+0.76)
How The CARERS Act Could Impact Pot Stocks
Michael Weiss - at Seeking Alpha - Mon Mar 30, 4:07AM CDT
CARA: 12.98 (+0.15), INSY: 62.10 (+0.76), GWPH: 113.04 (-0.05)
